Anavex Life Sciences Corp (AVXL)

[sokol]

George Perry, PhD, Dean and Professor at the University of Texas at San Antonio and Editor-in Chief of the Journal of Alzheimer’s Disease, commented, “Although this is an open label study with 32 patients, I have never seen mild-to-moderate Alzheimer’s patients maintain near baseline cognitive and activities of daily living function and positive correlation with all other measures over a 41-week trial period in any prior study with an approved or experimental drug. It is quite plausible that complex CNS diseases like Alzheimer’s may require a comprehensive approach, including restoration of cellular homeostasis.”

https://www.globenewswire.com/fr/news-release/2016/11/22/891996/0/en/Anavex-Life-Sciences-Announces-Data-on-41-Week-Treatment-of-ANAVEX-2-73-for-Patients-with-Alzheimer-s-Disease-Investigational-Treatment-suggests-to-curb-Cognitive-and-Functional-De.html